 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202203204» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Jul 2017 --> Sep 2018
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: ORAL STRATEGY: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (clinicaltrials.gov) - Jul 12, 2014
P4, N=1080, Not yet recruiting, Sponsor: Pfizer
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 (clinicaltrials.gov) - Jul 10, 2014
P3, N=270, Enrolling by invitation, Sponsor: AbbVie
- ||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment closed: SPIRIT-P1: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jul 8, 2014
P3, N=412, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Jul 2017 --> Sep 2018 Recruiting --> Active, not recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 4, 2014
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||| Trial completion, HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=1000, Completed, Sponsor: Jochen Schmitt.
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Completed
- fletikumab (NNC109-0012) / Novo Nordisk
Trial initiation date, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jul 1, 2014
P2, N=42, Not yet recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Completed Initiation date: Mar 2014 --> Sep 2014
- |||||||||| etrolizumab (RG7413) / Roche
New P3 trial: HIBISCUS II: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jun 26, 2014
P3, N=350, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: VISUAL l: Efficacy and Safety of Adalimumab in Patients With Active Uveitis (clinicaltrials.gov) - Jun 19, 2014
P3, N=266, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Mar 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change, Immune cell: A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=30 --> 0
- |||||||||| etrolizumab (RG7413) / Roche
New P3 trial: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jun 17, 2014
P3, N=350, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Humira (adalimumab) / Eisai, AbbVie
Clinical: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: Northwestern University
- |||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jun 13, 2014
P3, N=225, Recruiting, Sponsor: AbbVie
N=30 --> 0 Not yet recruiting --> Recruiting
- || Humira (adalimumab) / AbbVie
Trial primary completion date, HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=70, Not yet recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Jul 2016
- || Humira (adalimumab) / AbbVie
Trial initiation date, HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=70, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2016 --> Jul 2016 Initiation date: Mar 2014 --> Jul 2014
- Humira (adalimumab) / Eisai, AbbVie
PK/PD data, Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: AbbVie
Initiation date: Mar 2014 --> Jul 2014 Trial primary completion date: Jun 2015 --> Feb 2015
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 8, 2014
P=N/A, N=132, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2015 --> Feb 2015 N=305 --> 132
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, PK/PD data: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: AbbVie
N=305 --> 132 Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 8, 2014
P=N/A, N=132, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P=N/A, N=553, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| remtolumab (ABT-122) / AbbVie
Enrollment open, P2 data: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jun 1, 2014
P2, N=160, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Observational data, P4 data: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=566, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR, Real-world evidence, Real-world: Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=152, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - May 29, 2014
P=N/A, N=90, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Jul 2014
- ||| Humira (adalimumab) / AbbVie
New P3 trial: The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients (clinicaltrials.gov) - May 27, 2014
P3, N=30, Not yet recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
- Humira (adalimumab) / Eisai, AbbVie
Clinical: Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients (clinicaltrials.gov) - May 26, 2014
P=N/A, N=75, Recruiting, Sponsor: University Hospital, Ghent
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: RAPIDAt: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (clinicaltrials.gov) - May 26, 2014
P4, N=98, Recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / AbbVie
Trial completion, IO biomarker: An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR) (clinicaltrials.gov) - May 26, 2014
P=N/A, N=101, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Surveillance of Humira in Korean JIA Patients (clinicaltrials.gov) - May 22, 2014
P=N/A, N=600, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Initiation date: Aug 2014 --> May 2014
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Surveillance of Humira in Korean JIA Patients (clinicaltrials.gov) - May 22, 2014
P=N/A, N=600, Recruiting, Sponsor: AbbVie
Initiation date: Aug 2014 --> May 2014 Not yet recruiting --> Recruiting
- || Xeljanz (tofacitinib) / Pfizer, Enbrel (etanercept) / Pfizer, Amgen
Clinical: Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 21, 2014
P4, N=4000, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2019 --> Apr 2019
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) (clinicaltrials.gov) - May 18, 2014
P3, N=165, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jul 2019 --> Apr 2019 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Surveillance of Humira in Korean JIA Patients (clinicaltrials.gov) - May 18, 2014
P=N/A, N=600, Not yet recruiting, Sponsor: AbbVie
- ||||| remtolumab (ABT-122) / AbbVie
New P2 trial, P2 data: A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - May 18, 2014
P2, N=160, Not yet recruiting, Sponsor: AbbVie
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - May 15, 2014
P=N/A, N=5494, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Initiation date: Feb 2006 --> Jan 2006
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - May 15, 2014
P=N/A, N=5494, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Feb 2006 --> Jan 2006 N=4500 --> 5494
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - May 15, 2014
P=N/A, N=5494, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=4500 --> 5494 Active, not recruiting --> Completed
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Anti TNF α Improves Endothelial Dysfunction in IBD Patients (clinicaltrials.gov) - May 14, 2014
P4, N=20, Recruiting, Sponsor: Carmel Medical Center
Active, not recruiting --> Completed Initiation date: Jun 2013 --> May 2014
- Humira (adalimumab) / Eisai, AbbVie
Trial termination: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Initiation date: Jun 2013 --> May 2014 Recruiting --> Terminated; side effect and poor clinical outcome
- Humira (adalimumab) / Eisai, AbbVie
Trial completion date: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Recruiting --> Terminated; side effect and poor clinical outcome Trial completion date: Jun 2013 --> May 2014
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Trial completion date: Jun 2013 --> May 2014 N=10 --> 8
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER II: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - May 7, 2014
P3, N=326, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=10 --> 8 Trial primary completion date: May 2014 --> Apr 2014
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion date: PIONEER II: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - May 7, 2014
P3, N=326, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: May 2014 --> Apr 2014 Trial completion date: May 2014 --> Apr 2014
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PIONEER II: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - May 7, 2014
P3, N=326, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial completion date: May 2014 --> Apr 2014 Active, not recruiting --> Completed
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: SUSI-CS: Stavanger IBD Study - Cross Sectional (clinicaltrials.gov) - May 6, 2014
P=N/A, N=200, Recruiting, Sponsor: Helse Stavanger HF
- | New P4 trial: Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (clinicaltrials.gov) - May 5, 2014
P4, N=100, Recruiting, Sponsor: Jagiellonian University
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Enrollment open, HEOR: Evaluation of Health Costs and Resource Utilization (clinicaltrials.gov) - May 4, 2014
P4, N=160, Recruiting, Sponsor: University of Western Ontario, Canada
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
P4 data: A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) (clinicaltrials.gov) - May 2, 2014
P=N/A, N=1300, Not yet recruiting, Sponsor: AbbVie
- GSK2800528 / GSK
Trial primary completion date: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (clinicaltrials.gov) - Apr 30, 2014
P1, N=45, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Apr 2014
- GSK2800528 / GSK
Trial completion date: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (clinicaltrials.gov) - Apr 30, 2014
P1, N=45, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2014 --> Apr 2014 Trial completion date: Jan 2014 --> Apr 2014